RARE DISEASE
Sporadic Creutzfeldt-Jakob disease
Sporadic Creutzfeldt-Jakob disease
Sporadic Creutzfeldt-Jakob disease
Synonyms: Sporadic CJD
Synonyms: Sporadic CJD
Synonyms: Sporadic CJD
Drug discovery
2
drugs
With orphan designations
Overview
Sporadic Creutzfeldt-Jakob disease (sCJD) is a rapidly progressive, invariably fatal prion disorder characterized by dementia, myoclonus, visual/cerebellar disturbances, and akinetic mutism. Diagnosis relies on clinical criteria, MRI brain patterns (cortical/CSF biomarkers (14-3-3, RT-QuIC), and exclusion of mimics. Median survival is 4-8 months [1][9][13][14].
Burden
Therapies
Symptomatic management: Benzodiazepines for myoclonus, opioids for pain, antidepressants for mood [11][17]
Experimental approaches: Anti-prion monoclonal antibodies (PRN100), RNA interference, and neural precursor cell therapy show preclinical promise [3][7][19]
Clinical trials: Limited success with pentosan polysulfate/doxycycline; ASO-based gene suppression in development [7][19]
Categories: rare neurological diseases
Research Papers
319 drug discovery papers about Sporadic Creutzfeldt-Jakob disease, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
319 drug discovery papers about Sporadic Creutzfeldt-Jakob disease, with 1 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-08-10 | Formic acid treatment drastically reduces sporadic Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease infectivity in histological samples as tested in a high-sensitivity mouse bioassay.
Formic acid treatment is widely used in diagnostic neuropathology to reduce the infectivity of prion-containing tissues; however, quantitative in vivo evidence supporting its effectiveness under routine laboratory conditions remains limited. Here, we assessed the impact of formalin fixation and formic acid treatment on the infectivity of type 1 sporadic Creutzfeldt-Jakob disease (sCJD) and variant CJD (vCJD) prions using highly sensitive transgenic mouse models overexpressing human-PrP M129 (Hu-Tg340) or bovine PrP (Bo-Tg110). Brain tissues were processed under conditions closely resembling standard histopathological workflows and tested as untreated, formalin-fixed or formalin-plus-formic-acid-treated inocula. Untreated samples produced short incubation times and full attack rates, whereas formalin fixation caused only a modest prolongation of incubation times. In contrast, formic acid treatment markedly extended incubation times and reduced attack rates for sCJD. Based on incubation-time interpolation, the estimated infectivity reductions were on the order of 4.4 log₁₀ for vCJD and 5 log₁₀ for sCJD. These estimates indicate a major reduction in infectious titre under the conditions tested, although residual infectivity was still detected. The findings support formic acid treatment as an important risk-reduction step in routine neuropathology workflows for the two prion strains examined.
2026-06-30 | A scalable, dividing cell model for the robust propagation and quantification of human sporadic Creutzfeldt-Jakob disease prions.
Prion diseases represent a unique biological paradigm with mechanistic parallels to other neurodegenerative conditions like Alzheimer's and Parkinson's diseases. However, the study of human prion pathobiology and the development of effective therapeutics has been severely constrained by the inability to propagate human prions in dividing cells-forcing reliance on costly and slow animal bioassays. Here, we report the generation of EKV cells-a humanized cell model which supports the robust, indefinite propagation of sporadic Creutzfeldt-Jakob disease (sCJD) prions. We demonstrate that these cells replicate bona fide human prion infectivity in culture-cell lysates induce lethal neurodegeneration in humanized mice that is clinically and neuropathologically indistinguishable from inoculation with sCJD-infected brain tissue. We use EKV cells to develop the Human Prion Assay (HPA), which quantifies sCJD infectivity with sensitivity comparable to gold-standard mouse bioassay, while reducing the experimental timeline from years to weeks. Furthermore, we demonstrate that established sCJD infection can be cured by an anti-prion protein antibody, validating the system as a high-throughput platform for drug discovery. This model bridges a critical translational gap, offering a renewable alternative to animal bioassays, a paradigm to dissect the biology of human sCJD prion disease and screen for therapeutic agents.
2026-04-07 | Ferroptosis-related mechanisms in prion diseases provide insights into neurodegeneration and reveal therapeutic implications.
Prion diseases are a group of fatal neurodegenerative disorders caused by misfolded proteins. Understanding the regulatory networks of ferroptosis in prion diseases could unveil new diagnostic and therapeutic strategies. To explore this, we systematically evaluated ferroptosis-associated alterations across human sporadic Creutzfeldt-Jakob disease (sCJD) brain samples, the ME7-infected mouse model, and in vitro using PrP106-126-treated SH-SY5Y cells. In sCJD patients, we observed a significant decrease in GPX4 expression, accompanied by elevated lipid peroxidation, as confirmed by malondialdehyde assays. Furthermore, in vitro experiments using PrP106-126-treated cells confirmed that ferroptosis-related mechanisms actively contribute to cell death, characterized by elevated lipid peroxidation, reactive oxygen species, and increased intracellular Fe2+ levels, as well as diminished glutathione activity. Critically, pharmacological inhibition with ferrostatin-1 effectively mitigated this neurotoxicity, consistent with a ferroptosis-related mechanism. To validate these findings in vivo, we demonstrated that ME7-infected mice exhibited significantly lower levels of GPX4 and SLC7A11, which correlated with increased 4-hydroxynonenal and neuronal damage. Finally, bioinformatic analysis of the GSE124571 dataset identified a distinct transcriptomic signature of 130 differentially expressed ferroptosis-related genes in sCJD patients. These results collectively suggest that ferroptosis-associated alterations are involved in prion-associated neurodegeneration, offering valuable pathophysiological insights into disease progression.
2026-03-09 | Prion Diseases as Attractor Medicine: Conformational False Attractors, Cross-Species Resistance, and Drug Target Derivation from the Identity Axis Framework
This paper extends the Identity Axis Framework (R = A/H) — previously applied to cancer, neurodegeneration, and psychiatric disease — to prion diseases, establishing a new table class: the protein conformational false attractor (Class 2 / Level 4). We derive why prion diseases are geometrically distinct from all other entries in the Attractor Medicine table: the unit of identity failure is not a cell but a single protein molecule, and the false attractor (PrPSc, beta-sheet conformation) is thermodynamically self-maintaining without an enzymatic Hub. The R_PRION coordinate (energy barrier to false conformation / PrPSc templating efficiency) is introduced and validated against the cross-species resistance data: dogs (D163), rabbits (S174), horses (S167), and the Fore people of Papua New Guinea (G127V, Mead et al., NEJM 2015). The Fore G127V evolution — complete prion resistance from a single amino acid change in four generations — is identified as the clearest documented case of natural selection raising R_PRION by reinforcing the Identity Anchor of a protein. The standard Tier 2 Hub inhibitor drug logic fails for prion disease (the Hub is not a separate enzyme but the misfolded conformation itself), and the correct drug logic is derived to be substrate removal (ION717 PRNP-ASO, Phase 1/2, 2024) combined with conformation stabilisation (anle138b). A Tier 3 intervention — base editing G127V in PRNP — is derived as a permanent synthetic equivalent of the Fore evolution. The document introduces the four-level taxonomy of identity failure (gene regulatory, circuit connectivity, temporal/phase, protein conformational), unifies the Level 4 drug platform across all propagating protein diseases (prion, Alzheimer's tau, Parkinson's alpha-syn, Huntington's mHTT, ALS TDP-43), and derives the coupling between lifespan extension and sporadic CJD risk as a direct implication of the anti-aging framework. Nine claims are verified against published evidence; three novel predictions are locked with this timestamp.
2026-01-01 | PRION BIOLOGY AND CREUTZFELDT–JAKOB DISEASE: FROM MISFOLDED PROTEINS TO CLINICAL IMPLICATIONS
Creutzfeldt–Jakob disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder belonging to the group of transmissible spongiform encephalopathies, characterized by the accumulation of misfolded prion proteins (PrP^Sc) in the central nervous system. The pathogenesis involves conformational conversion of the normal cellular prion protein (PrP^C) into its pathogenic isoform, initiating a cascade of neurotoxicity, neuronal loss, and spongiform changes. CJD manifests in sporadic, genetic, and acquired forms, with clinical features including rapidly progressive dementia, myoclonus, visual disturbances, and cerebellar ataxia. Advances in diagnostic modalities—such as real-time quaking-induced conversion (RT-QuIC), magnetic resonance imaging (MRI) signal changes, and cerebrospinal fluid biomarkers—have improved early detection, yet definitive diagnosis remains postmortem through neuropathological examination. Despite intensive research, no curative therapy exists; management remains supportive, underscoring the urgency for therapeutic breakthroughs. Recent studies have explored anti-prion compounds, immunotherapeutic approaches, and gene-targeting strategies, showing promise in preclinical models. This review synthesizes current knowledge on prion biology, molecular mechanisms of disease, diagnostic advancements, and emerging therapeutic strategies, with the aim of bridging the gap between bench research and clinical application. Understanding the intricate relationship between prion protein misfolding and neurodegeneration may pave the way for targeted interventions in CJD and related prion diseases.
2026-08-10 | Formic acid treatment drastically reduces sporadic Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease infectivity in histological samples as tested in a high-sensitivity mouse bioassay.
Formic acid treatment is widely used in diagnostic neuropathology to reduce the infectivity of prion-containing tissues; however, quantitative in vivo evidence supporting its effectiveness under routine laboratory conditions remains limited. Here, we assessed the impact of formalin fixation and formic acid treatment on the infectivity of type 1 sporadic Creutzfeldt-Jakob disease (sCJD) and variant CJD (vCJD) prions using highly sensitive transgenic mouse models overexpressing human-PrP M129 (Hu-Tg340) or bovine PrP (Bo-Tg110). Brain tissues were processed under conditions closely resembling standard histopathological workflows and tested as untreated, formalin-fixed or formalin-plus-formic-acid-treated inocula. Untreated samples produced short incubation times and full attack rates, whereas formalin fixation caused only a modest prolongation of incubation times. In contrast, formic acid treatment markedly extended incubation times and reduced attack rates for sCJD. Based on incubation-time interpolation, the estimated infectivity reductions were on the order of 4.4 log₁₀ for vCJD and 5 log₁₀ for sCJD. These estimates indicate a major reduction in infectious titre under the conditions tested, although residual infectivity was still detected. The findings support formic acid treatment as an important risk-reduction step in routine neuropathology workflows for the two prion strains examined.
2026-06-30 | A scalable, dividing cell model for the robust propagation and quantification of human sporadic Creutzfeldt-Jakob disease prions.
Prion diseases represent a unique biological paradigm with mechanistic parallels to other neurodegenerative conditions like Alzheimer's and Parkinson's diseases. However, the study of human prion pathobiology and the development of effective therapeutics has been severely constrained by the inability to propagate human prions in dividing cells-forcing reliance on costly and slow animal bioassays. Here, we report the generation of EKV cells-a humanized cell model which supports the robust, indefinite propagation of sporadic Creutzfeldt-Jakob disease (sCJD) prions. We demonstrate that these cells replicate bona fide human prion infectivity in culture-cell lysates induce lethal neurodegeneration in humanized mice that is clinically and neuropathologically indistinguishable from inoculation with sCJD-infected brain tissue. We use EKV cells to develop the Human Prion Assay (HPA), which quantifies sCJD infectivity with sensitivity comparable to gold-standard mouse bioassay, while reducing the experimental timeline from years to weeks. Furthermore, we demonstrate that established sCJD infection can be cured by an anti-prion protein antibody, validating the system as a high-throughput platform for drug discovery. This model bridges a critical translational gap, offering a renewable alternative to animal bioassays, a paradigm to dissect the biology of human sCJD prion disease and screen for therapeutic agents.
2026-04-07 | Ferroptosis-related mechanisms in prion diseases provide insights into neurodegeneration and reveal therapeutic implications.
Prion diseases are a group of fatal neurodegenerative disorders caused by misfolded proteins. Understanding the regulatory networks of ferroptosis in prion diseases could unveil new diagnostic and therapeutic strategies. To explore this, we systematically evaluated ferroptosis-associated alterations across human sporadic Creutzfeldt-Jakob disease (sCJD) brain samples, the ME7-infected mouse model, and in vitro using PrP106-126-treated SH-SY5Y cells. In sCJD patients, we observed a significant decrease in GPX4 expression, accompanied by elevated lipid peroxidation, as confirmed by malondialdehyde assays. Furthermore, in vitro experiments using PrP106-126-treated cells confirmed that ferroptosis-related mechanisms actively contribute to cell death, characterized by elevated lipid peroxidation, reactive oxygen species, and increased intracellular Fe2+ levels, as well as diminished glutathione activity. Critically, pharmacological inhibition with ferrostatin-1 effectively mitigated this neurotoxicity, consistent with a ferroptosis-related mechanism. To validate these findings in vivo, we demonstrated that ME7-infected mice exhibited significantly lower levels of GPX4 and SLC7A11, which correlated with increased 4-hydroxynonenal and neuronal damage. Finally, bioinformatic analysis of the GSE124571 dataset identified a distinct transcriptomic signature of 130 differentially expressed ferroptosis-related genes in sCJD patients. These results collectively suggest that ferroptosis-associated alterations are involved in prion-associated neurodegeneration, offering valuable pathophysiological insights into disease progression.
2026-03-09 | Prion Diseases as Attractor Medicine: Conformational False Attractors, Cross-Species Resistance, and Drug Target Derivation from the Identity Axis Framework
This paper extends the Identity Axis Framework (R = A/H) — previously applied to cancer, neurodegeneration, and psychiatric disease — to prion diseases, establishing a new table class: the protein conformational false attractor (Class 2 / Level 4). We derive why prion diseases are geometrically distinct from all other entries in the Attractor Medicine table: the unit of identity failure is not a cell but a single protein molecule, and the false attractor (PrPSc, beta-sheet conformation) is thermodynamically self-maintaining without an enzymatic Hub. The R_PRION coordinate (energy barrier to false conformation / PrPSc templating efficiency) is introduced and validated against the cross-species resistance data: dogs (D163), rabbits (S174), horses (S167), and the Fore people of Papua New Guinea (G127V, Mead et al., NEJM 2015). The Fore G127V evolution — complete prion resistance from a single amino acid change in four generations — is identified as the clearest documented case of natural selection raising R_PRION by reinforcing the Identity Anchor of a protein. The standard Tier 2 Hub inhibitor drug logic fails for prion disease (the Hub is not a separate enzyme but the misfolded conformation itself), and the correct drug logic is derived to be substrate removal (ION717 PRNP-ASO, Phase 1/2, 2024) combined with conformation stabilisation (anle138b). A Tier 3 intervention — base editing G127V in PRNP — is derived as a permanent synthetic equivalent of the Fore evolution. The document introduces the four-level taxonomy of identity failure (gene regulatory, circuit connectivity, temporal/phase, protein conformational), unifies the Level 4 drug platform across all propagating protein diseases (prion, Alzheimer's tau, Parkinson's alpha-syn, Huntington's mHTT, ALS TDP-43), and derives the coupling between lifespan extension and sporadic CJD risk as a direct implication of the anti-aging framework. Nine claims are verified against published evidence; three novel predictions are locked with this timestamp.
2026-01-01 | PRION BIOLOGY AND CREUTZFELDT–JAKOB DISEASE: FROM MISFOLDED PROTEINS TO CLINICAL IMPLICATIONS
Creutzfeldt–Jakob disease (CJD) is a rare, fatal, and rapidly progressive neurodegenerative disorder belonging to the group of transmissible spongiform encephalopathies, characterized by the accumulation of misfolded prion proteins (PrP^Sc) in the central nervous system. The pathogenesis involves conformational conversion of the normal cellular prion protein (PrP^C) into its pathogenic isoform, initiating a cascade of neurotoxicity, neuronal loss, and spongiform changes. CJD manifests in sporadic, genetic, and acquired forms, with clinical features including rapidly progressive dementia, myoclonus, visual disturbances, and cerebellar ataxia. Advances in diagnostic modalities—such as real-time quaking-induced conversion (RT-QuIC), magnetic resonance imaging (MRI) signal changes, and cerebrospinal fluid biomarkers—have improved early detection, yet definitive diagnosis remains postmortem through neuropathological examination. Despite intensive research, no curative therapy exists; management remains supportive, underscoring the urgency for therapeutic breakthroughs. Recent studies have explored anti-prion compounds, immunotherapeutic approaches, and gene-targeting strategies, showing promise in preclinical models. This review synthesizes current knowledge on prion biology, molecular mechanisms of disease, diagnostic advancements, and emerging therapeutic strategies, with the aim of bridging the gap between bench research and clinical application. Understanding the intricate relationship between prion protein misfolding and neurodegeneration may pave the way for targeted interventions in CJD and related prion diseases.
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Sporadic Creutzfeldt-Jakob disease.
2 orphan drug designations for Sporadic Creutzfeldt-Jakob disease.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
N,N'-([Cyclohexylmethylene]di-4,1-phenylene)bis(2-[1-pyrrolidinyl]acetamide) | small molecules | EMA | 2024-07-25 | — | RegSmart Life Science AB |
Pentamer formyl thiophene acetic acid | small molecules | EMA | 2017-06-20 | — | NeuroScios GmbH |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.